28 related articles for article (PubMed ID: 38599011)
1. VHL mutation drives human clear cell renal cell carcinoma progression through PI3K/AKT-dependent cholesteryl ester accumulation.
Zhang S; Fang T; He Y; Feng W; Yu Z; Zheng Y; Zhang C; Hu S; Liu Z; Liu J; Yu J; Zhang H; He A; Gong Y; He Z; Yang K; Xi Z; Yu W; Zhou L; Yao L; Yue S
EBioMedicine; 2024 May; 103():105070. PubMed ID: 38564827
[TBL] [Abstract][Full Text] [Related]
2. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
[TBL] [Abstract][Full Text] [Related]
3. Derivative Chromosome 3 Loss from t(3;6)(q12;q14) Followed by Differential
Mizutani K; Yokoi S; Sawada S; Sakamoto I; Kameyama K; Kamei S; Hirade K; Sugiyama S; Matsunaga K; Yamada T; Kato Y; Nishihara H; Ishihara S; Deguchi T
Cancer Genomics Proteomics; 2022; 19(6):740-746. PubMed ID: 36316043
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of von Hippel-Lindau protein-mediated suppression of nuclear factor kappa B activity.
An J; Rettig MB
Mol Cell Biol; 2005 Sep; 25(17):7546-56. PubMed ID: 16107702
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of
Stransky LA; Vigeant SM; Huang B; West D; Denize T; Walton E; Signoretti S; Kaelin WG
Proc Natl Acad Sci U S A; 2022 Apr; 119(14):e2120403119. PubMed ID: 35357972
[TBL] [Abstract][Full Text] [Related]
6. Cholesterol accumulation in ccRCC: the role of ccRCC-initiating VHL-HIFα pathway.
Mohtar MA; Hasanah Mohd Yusuf SN; Syafruddin SE
EBioMedicine; 2024 May; 103():105112. PubMed ID: 38599011
[No Abstract] [Full Text] [Related]
7. Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status.
Tumkur Sitaram R; Landström M; Roos G; Ljungberg B
J Clin Pathol; 2021 Apr; 74(4):216-222. PubMed ID: 32467322
[TBL] [Abstract][Full Text] [Related]
8. Chromosome 3p Loss-Orchestrated VHL, HIF, and Epigenetic Deregulation in Clear Cell Renal Cell Carcinoma.
Hsieh JJ; Le VH; Oyama T; Ricketts CJ; Ho TH; Cheng EH
J Clin Oncol; 2018 Oct; 36(36):JCO2018792549. PubMed ID: 30372397
[TBL] [Abstract][Full Text] [Related]
9. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy.
Clark PE
Kidney Int; 2009 Nov; 76(9):939-45. PubMed ID: 19657325
[TBL] [Abstract][Full Text] [Related]
10. The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Cinque A; Minnei R; Floris M; Trevisani F
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358771
[TBL] [Abstract][Full Text] [Related]
11. Alterations in VHL as potential biomarkers in renal-cell carcinoma.
Gossage L; Eisen T
Nat Rev Clin Oncol; 2010 May; 7(5):277-88. PubMed ID: 20368728
[TBL] [Abstract][Full Text] [Related]
12. Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation.
Khacho M; Lee S
Future Oncol; 2009 Feb; 5(1):85-95. PubMed ID: 19243301
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
